A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

(2013) S. Lyford-Pike et al.   CANCER RESEARCH

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

(2013) Wim H.J. Kruit et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer

(2013) Aimée R. Kreimer et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

(2013) Johan Vansteenkiste et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective

(2012) D. T. Le et al.   CANCER RESEARCH

inducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma

(2012) Caroline J. Voskens et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression

(2012) Suzanne Ostrand-Rosenberg et al.   SEMINARS IN CANCER BIOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Improving vaccine delivery using novel adjuvant systems

(2011) Michael E. Pichichero   Human vaccines & immunotherapeutics

ACR Appropriateness Criteria® Retreatment of Recurrent Head and Neck Cancer After Prior Definitive Radiation

(2011) Mark W. McDonald et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The clinical implications of antitumor immunity in head and neck cancer

(2011) Clint T. Allen et al.   LARYNGOSCOPE

Optimal treatment for recurrent/metastatic head and neck cancer

(2010) J. B. Vermorken et al.   ANNALS OF ONCOLOGY

High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx

(2010) David L. A. Figueiredo et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Therapeutic cancer vaccines: are we there yet?

(2010) Christopher A. Klebanoff et al.   IMMUNOLOGICAL REVIEWS

Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma

(2010) Cyril Cuffel et al.   INTERNATIONAL JOURNAL OF CANCER

Down-Regulation of HLA Class I Antigen in Human Papillomavirus Type 16 E7 Expressing HaCaT Cells

(2010) Wei Li et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells

(2010) M.S. Campo et al.   VIROLOGY

Synthetic Peptide-Based Cancer Vaccines: Lessons Learned and Hurdles to Overcome

(2009) Caroline Voskens et al.   CURRENT MOLECULAR MEDICINE

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

(2008) G. G. Kenter et al.   CLINICAL CANCER RESEARCH